Secondary analysis of the START trial (1199 ART-naive people with HIV, CD4 >500): anti-CD4 autoantibody prevalence was 41% at baseline and at month 24 was 26% with immediate vs 31% with deferred ART (OR 2.04; P<.001); autoantibodies were not linked to CD4 recovery.
Secondary analysisn = 1,199
Epling et al. Effect of Delayed Antiretroviral Therapy Initiation on Anti-CD4 Autoantibodies in Antiretroviral Therapy-Naive People With HIV